Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Division of Psychiatric Research, Zucker Hillside Hospital, NY, USA; 2Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; 3Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany; 4Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA; 5Division of Child and Adolescent Psychiatry, School of Medicine, University of Maryland, Baltimore, MD, USA; 6SAS Institute, Cary, NC, USA; 7Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA; 8Department of Science Education, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; 9Duke Clinical Research Institute, Durham, NC, USA; 10Hughes Center, Danville, VA, USA; 11Department of Psychiatry, University of North Carolina, Chapel Hill, NC, USA
Список исп. литературыСкрыть список 1. Olfson M, Blanco C, Wang S et al. National trends in the mental health care of children, adolescents, and adults by office-based physicians. JAMA Psychiatry 2014;71:81-90 2. Vancampfort D, Correll CU, Galling B et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry 2016;15:166-74. 3. Vancampfort D, Stubbs B, Mitchell AJ et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015;14:339-47. 4. De Hert M, Detraux J, van Winkel R et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011;8:114-26. 5. Correll CU, Manu P, Olshanskiy V et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765-73. 6. Galling B, Roldan A, Nielsen RE et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry 2016;73:247-59. 7. Arango C, Giraldez M, Merchan-Naranjo J et al. Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naive patients. J Am Acad Child Adolesc Psychiatry 2014;53:1179-90. 8. Correll CU, Solmi M, Veronese N et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 2017;16:163-80. 9. Morrato EH, Campagna EJ, Brewer SE et al. Metabolic testing for adults in a state Medicaid program receiving antipsychotics: remaining barriers to achieving population health prevention goals. JAMA Psychiatry 2016;73:721-30. 10. Mitchell AJ, Delaffon V, Vancampfort D et al. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 2012;42:125-47. 11. Morrato EH, Nicol GE, Maahs D et al. Metabolic screening in children receiving antipsychotic drug treatment. Arch Pediatr Adolesc Med 2010;164:344-51. 12. Rodday AM, Parsons SK, Mankiw C et al. Child and adolescent psychiatrists’ reported monitoring behaviors for second-generation antipsychotics. J Child Adolesc Psychopharmacol 2015;25:351-61. 13. Raebel MA, Penfold R, McMahon AW et al. Adherence to guidelines for glucose assessment in starting second-generation antipsychotics. Pediatrics 2014;134:e1308-14. 14. Vancampfort D, Firth J, Correll CU et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry 2019;18:53-66. 15. Firth J, Siddiqi N, Koyanagi A et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry 2019;6:675-712. 16. Must A, Jacques PF, Dallal GE et al. Long-term morbidity and mortality of overweight adolescents – a follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med 1992;327:1350-5. 17. Baker JL, Olsen LW, Sorensen TI. Childhood body-mass index and the risk of coronary heart disease in adult. N Engl J Med 2007;357:2329-37. 18. Speyer H, Jakobsen AS, Westergaard C et al. Lifestyle interventions for weight management in people with serious mental illness: a systematic review with meta-analysis, trial sequential analysis, and meta-regression analysis exploring the mediators and moderators of treatment effects. Psychother Psychosom (in press). 19. Mukundan A, Faulkner G, Cohn T et al. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev 2010;12:CD006629. 20. Correll CU, Maayan L, Kane J et al. Efficacy for psychopathology and body weight and safety of topiramate-antipsychotic cotreatment in patients with schizophrenia spectrum disorders: results from a meta-analysis of randomized controlled trials. J Clin Psychiatry 2016;77:e746-56. 21. Zheng W, Li XB, Tang YL et al. Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol 2015;35:499-509. 22. Speyer H, Norgaard HCB, Birk M et al. The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity. World Psychiatry 2016;15:155-65. 23. Detke HC, DelBello MP, Landry J et al. A 52-week study of olanzapine with a randomized behavioral weight counseling intervention in adolescents with schizophrenia or bipolar I disorder. J Child Adolesc Psychopharmacol 2016;26:922-34. 24. Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes 2014;21:323-9. 25. Klein DJ, Cottingham EM, Sorter M et al. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006;163:2072-9. 26. Arman S, Sadramely MR, Nadi M et al. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med J 2008;29:1130-4. 27. Anagnostou E, Aman MG, Handen BL et al. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: a randomized clinical trial. JAMA Psychiatry 2016;73:928-37. 28. Reeves GM, Keeton C, Correll CU et al. Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods. Child Adolesc Psychiatry Ment Health 2013;7:31. 29. Leibenluft E, Charney DS, Towbin KE et al. Defining clinical phenotypes of juvenile mania. Am J Psychiatry 2003;160:430-7. 30. Kaufman J, Birmaher B, Brent D et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children – Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997;36:980-8. 31. Busner J, Targum SD. The Clinical Global Impressions Scale: applying a research tool in clinical practice. Psychiatry 2007;4:28-37. 32. Chapman LE, Darling AL, Brown JE. Association between metformin and vitamin B12 deficiency in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab 2016;42:316-27. 33. Sikich L, Frazier JA, McClellan J et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. Am J Psychiatry 2008;165:1420-31. 34. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23. 35. Hughes CW, Rintelmann J, Emslie GJ et al. A revised anchored version of the BPRS-C for childhood psychiatric disorders. J Child Adolesc Psychopharmacol 2001;11:77-93. 36. Greenhill LL, Vitiello B, Fisher P et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2004;43:1488-96. 37. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;45(Suppl. 212):11-9. 38. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6. 39. Lane RD, Glazer WM, Hansen TE et al. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis 1985;173:353-7. 40. Barlow SE. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007;120(Suppl. 4):S164-92. 41. Kolotkin RL, Crosby RD, Corey-Lisle PK et al. Performance of a weight-related measure of quality of life in a psychiatric sample. Qual Life Res 2006;15:587-96. 42. Arnau J, Bendayan R, Blanca MJ et al. Should we rely on the Kenward-Roger approximation when using linear mixed models if the groups have different distributions? Br J Math Statist Psychol 2014;67:408-29. 43. Derakhshan F, Toth C. Insulin and the brain. Curr Diabetes Rev 2013;9:102-16. 44. Mostafa DK, Ismail CA, Ghareeb DA. Differential metformin dose-dependent effects on cognition in rats: role of Akt. Psychopharmacology 2016;233:2513-24. 45. Stroup TS, McEvoy JP, Ring KD et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011;168:947-56. 46. Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 2008;47:9-20. 47. Kane JM, Skuban A, Hobart M et al. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr Res 2016;174:93-8. 48. Citrome L. Cariprazine for the treatment of schizophrenia: a review of this dopamine D3-preferring D3/D2 receptor partial agonist. Clin Schizophr Relat Psychoses 2016;10:109-19. 49. Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol 2004;14:243-54. 50. Penzner JB, Dudas M, Saito E et al. Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol 2009;19:563-73. 51. Correll CU, Sikich L, Reeves G et al. Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long? Am J Psychiatry 2013;170:947-52. 52. Correll CU, Blader JC. Antipsychotic use in youth without psychosis: a double-edged sword. JAMA Psychiatry 2015;72:859-60.